Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression: adenoviral infection vs stable transfection.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Min JJ;Min JJ; Iyer M; Gambhir SS
- Source:
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2003 Nov; Vol. 30 (11), pp. 1547-60. Date of Electronic Publication: 2003 Jul 10.
- Publication Type:
Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
- Language:
English
- Additional Information
- Source:
Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1619-7070 (Print) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE
- Publication Information:
Original Publication: Berlin : Springer-Verlag Berlin, 2002-
- Subject Terms:
- Abstract:
Earlier studies involving comparison of different reporter probes have shown conflicting results between pyrimidine nucleosides [e.g., 2'-fluoro-2'-deoxy-1-beta- d-arabinofuranosyl-5-iodouracil (FIAU)] and acycloguanosine derivatives [e.g., penciclovir (PCV), 9-(4-fluoro-3-hydroxymethylbutyl)guanine (FHBG)]. We hypothesized that this reported discrepancy may be related to how the reporter gene is delivered to the cells-stably transfected vs adenoviral infection. We directly compared the uptake characteristics of [(18)F]FHBG, [(3)H]PCV, and [(14)C]FIAU in cell culture and in vivo using an adenoviral mediated gene transfer model and stably transfected cells. We further compared the uptake of three reporter probes using both HSV1-tk and a mutant HSV1-sr39tk expressing cells to assess the optimal reporter probe/reporter gene combination. [(14)C]FIAU accumulation was greater than that of [(3)H]PCV and [(18)F]FHBG in control cells and in HSV1-tk stably transfected cells ( P<0.001). After infection of C6 cells with AdCMV- HSV1-tk (1.5x10(8) pfu), [(18)F]FHBG and [(3)H]PCV accumulation was significantly greater than that of [(14)C]FIAU ( P<0.01). [(18)F]FHBG and [(3)H]PCV accumulated to a significantly greater extent than [(14)C]FIAU in C6-stb-sr39tk+ and AdCMV- HSV1-sr39tk infected C6 cells ( P<0.001). Results from the nude mice supported the results in cell culture. [(14)C]FIAU led to significantly higher %ID/g in C6-stb-tk+ xenografts than [(18)F]FHBG ( P<0.05); however, compared with [(14)C]FIAU, [(18)F]FHBG led to as high %ID/g in HSV1-tk expressing hepatocytes and to significantly greater %ID/g in C6-stb-sr39tk+ xenografts and HSV1-sr39tk expressing hepatocytes. Dynamic sequential images showed that [(18)F]FHBG was well retained in HSV1-sr39tk expressing cells (C6-stb-sr39tk+) for at least 4 h after injection, while it was rapidly cleared from HSV1-tk expressing cells (MH3924A-stb-tk+). [(14)C]FIAU accumulated in HSV1-tk stably expressing cells to a greater extent than either [(3)H]PCV or [(18)F]FHBG. However, the accumulation of [(3)H]PCV and [(18)F]FHBG in adenoviral infected C6 cells or hepatocytes was equivalent to or greater than that of [(14)C]FIAU. These results may be due to intracellular biochemical changes (e.g., thymidine) when cells are infected with adenovirus. For adenoviral studies, the [(18)F]FHBG/ HSV1-sr39tk combination was shown to be more sensitive than the [(14)C]FIAU/ HSV1-tk combination HSV1-tk.
- References:
J Nucl Med. 2001 Jan;42(1):96-105. (PMID: 11197989)
Phys Med Biol. 1998 Apr;43(4):1001-13. (PMID: 9572523)
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6961-6. (PMID: 11997447)
Eur J Nucl Med. 2001 Jun;28(6):721-9. (PMID: 11440032)
Neoplasia. 2000 Jan-Apr;2(1-2):118-38. (PMID: 10933072)
Gene Ther. 2001 Jul;8(14):1072-80. (PMID: 11526454)
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2785-90. (PMID: 10716999)
Nucl Med Biol. 1999 May;26(4):371-6. (PMID: 10382839)
Cancer Res. 2003 Mar 15;63(6):1160-5. (PMID: 12649169)
Nucleosides Nucleotides. 1999 Apr-May;18(4-5):1065-6. (PMID: 10432739)
Biochem Pharmacol. 1991 Jan 15;41(2):263-71. (PMID: 1989636)
Nucl Med Biol. 1998 May;25(4):367-73. (PMID: 9639298)
Biochim Biophys Acta. 1988 Oct 11;947(3):405-43. (PMID: 3048401)
Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1547-60. (PMID: 14579096)
Nat Med. 2000 Aug;6(8):933-7. (PMID: 10932234)
Cancer Res. 1996 Sep 15;56(18):4087-95. (PMID: 8797571)
Biochem Pharmacol. 1977 Nov 15;26(22):2175-9. (PMID: 412502)
Nucl Med Biol. 1998 Apr;25(3):175-80. (PMID: 9620620)
Nucl Med Biol. 2000 Feb;27(2):113-9. (PMID: 10773539)
Cancer Res. 1999 Oct 15;59(20):5186-93. (PMID: 10537296)
Cancer Res. 1995 Dec 15;55(24):6126-32. (PMID: 8521403)
J Nucl Med. 1997 Feb;38(2):287-94. (PMID: 9025757)
J Biol Chem. 1992 Nov 5;267(31):22272-6. (PMID: 1429579)
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2333-8. (PMID: 10051642)
J Nucl Med. 2002 Aug;43(8):1072-83. (PMID: 12163634)
J Nucl Med. 1998 Nov;39(11):2003-11. (PMID: 9829598)
Cancer Res. 1998 Oct 1;58(19):4333-41. (PMID: 9766661)
Gene Ther. 2001 Oct;8(20):1572-9. (PMID: 11704818)
- Grant Information:
P50 CA86306 United States CA NCI NIH HHS; R0-1 CA82214 United States CA NCI NIH HHS; R24 CA92865 United States CA NCI NIH HHS
- Accession Number:
0 (9-(4-fluoro-3-hydroxymethylbutyl)guanine)
0 (Intracellular Signaling Peptides and Proteins)
0 (MON1B protein, human)
0 (Proteins)
0 (Radiopharmaceuticals)
3083-77-0 (Arabinofuranosyluracil)
53T7IN77LC (fialuridine)
5Z93L87A1R (Guanine)
- Publication Date:
Date Created: 20031028 Date Completed: 20040806 Latest Revision: 20210107
- Publication Date:
20231215
- Accession Number:
10.1007/s00259-003-1238-6
- Accession Number:
14579096
_0.png)
No Comments.